Novo’s obesity contender Saxenda wins US approval
The FDA has approved Novo Nordisk's obesity drug Saxenda for the US market. The drug is expected to break comfortably through the billion-dollar sales market within the next ten years, earning it blockbuster status.
BY STEFAN SINGH KAILAY
The holidays came early this year, as an early Christmas gift was sent from Washington to Bagsværd.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Fresh data support Saxenda's potential
For abonnenter
